Quick recap The meeting focused on Kratom advocacy, recent state-level bans, and the distinction between natural Kratom and synthetic products like 7-OH. Christopher, Julianna, Paul, Michael, Venus, and Kelly discussed the emergency ban in Massachusetts, concerns about state versus federal regulation, and the role of the FDA website in shaping state policies. They shared experiences with 7-OH, including addiction, withdrawal, and the lack of transparency in smoke shop products, contrasting this with third-party tested natural Kratom. The group discussed advocacy strategies, including using COAs, testifying at hearings, and prioritizing consumer voices over vendor interests. They also covered issues around cannabis and hemp laws in Texas and other states, interactions with doctors, and the broader political and social context of plant medicine. The conversation included personal stories of pain management, addiction, and the impact of Kratom on users’ lives, as well as frustration with misinformation, media portrayals, and anti-Kratom activists. Kratom Regulation Discussion Christopher and Julianna discussed the setup for an upcoming call about Kratom, noting that several regular participants, including Paul, a founder of the American Kratom Association, would be joining. The conversation shifted to recent developments in Massachusetts regarding Kratom regulation, with Christopher expressing concerns about the governor's announcement and potential pushback from the community. The discussion ended with Christopher mentioning a previous conversation with an FDA representative about how the agency's website content might be influencing state-level Kratom bans. Kratom Regulatory Challenges Discussion Christopher discussed the regulatory challenges surrounding Kratom, explaining that while the FDA doesn't approve dietary supplements, states can still implement their own regulations regardless of federal guidance. He expressed concern about potentially high state registration fees per product, which could make operating as an online vendor unsustainable, and highlighted his commitment to following strict testing protocols under 21 CFR 111. The conversation also touched on the rise of 7OH in Kratom products, with Christopher explaining how smoke shops misleadingly marketed it as "new Kratom" while it contains synthetic compounds that can be addictive and harmful at higher doses.

Quick recap The meeting focused on the ongoing challenges and advocacy efforts surrounding Kratom regulation and industry practices. Christopher, Paul, and Michael discussed recent hearings, including one in Westchester, where they argued against local bans and emphasized the need for federal leadership. They criticized the tactics of anti-Kratom groups and highlighted the distinction between natural Kratom and problematic synthetic products like 7-OH. The conversation covered industry issues such as product quality, testing, and the need for reasonable federal regulations. They also discussed the role of smoke shops and gas stations in selling Kratom, the impact of adulterated products, and the importance of consumer education. The group shared personal experiences with Kratom and extracts, expressing concerns about high-dose products and the potential for misuse. They also touched on broader topics like the influence of pharmaceutical companies, political donations, and the challenges faced by small vendors in a regulatory environment. Summary Kratom Regulation Advocacy Updates The group discussed their recent involvement in a hearing in Westchester where they successfully opposed local ordinances that were seen as overreaching on kratom regulation. Paul mentioned writing a letter to the Georgia Blue Ribbon Committee, which Michael confirmed he would also do. The conversation touched on ongoing challenges with federal agencies like the FDA and DEA, with participants expressing frustration about the influence of pharmaceutical companies and what they viewed as a "deep state" within regulatory bodies. Kratom Vendor Hearing Discussion Christopher explained his motivation for participating in a hearing about Kratom, emphasizing that as a small online vendor, he has no financial stake in local bans and is simply sharing his personal experience with how Kratom helped him. He discussed the importance of proper product labeling and testing, sharing his company's lab testing results as an example of quality practices in the industry. Christopher also mentioned that government drug control strategies are increasingly targeting various products sold in smoke shops, not just Kratom, suggesting a broader regulatory shift against this retail environment.

https://christophersorganicbotanicals.com/kratom-alkaloids-in-human-plasma-2026-study/

https://christophersorganicbotanicals.com/kratom-testing-results/